|
| Press Releases |
|
 |
|
| Wednesday, July 16, 2025 |
|
|
AATec Medical 與 Northway Biotech 宣布合作開發用於治療肺部疾病的 ATL-105 工業化生產工藝 |
| AATec Medical GmbH（以下簡稱「AATec」）是一家致力於開發用於治療呼吸系統疾病多產品平台的生物技術公司。Northway Biotech（以下簡稱「Northway Biotech」或「NBT」）是一家全球合同開發與製造組織（CDMO）。兩家公司今日宣布建立合作關係，聯合開展 AATec 旗下主要候選產品 ATL-105 的生產製程開發與分析方法開發。ATL-105 是一種專有的重組 α1-抗胰蛋白酶（AAT）吸入式療法，適用於治療非囊性纖維化支氣管擴張症（NCFB）。 more info >> |
|
|
AATec Medical 与 Northway Biotech 宣布合作开发用于治疗肺部疾病的 ATL-105 工业化生产工艺 |
| AATec Medical GmbH（简称“AATec”）是一家致力于开发用于治疗呼吸系统疾病的多产品平台的生物技术公司。 Northway Biotech（简称“Northway Biotech”或“NBT”）是一家全球合同开发与制造组织（CDMO）。两家公司今日宣布建立合作关系，联合开展 AATec 旗下主要候选产品 ATL-105 的生产工艺开发与分析方法开发。ATL-105 是一种专有的重组 α1-抗胰蛋白酶（AAT）吸入式疗法，适用于治疗非囊性纤维化支气管扩张症（NCFB）。 more info >> |
|
| Tuesday, July 15, 2025 |
|
|
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease |
| AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB). more info >> |
|
| Monday, May 5, 2025 |
|
|
Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards |
| Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech's new Gene Therapy Center with dedicated cGMP facilities for virus-related projects. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
Micreos Pharmaceuticals 與生物製劑 CDMO Northway Biotech 合作推動其工程化內溶素療法製造計畫 |
| more info >> |
|
|
Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program |
| Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis. more info >> |
|
| Wednesday, February 5, 2025 |
|
|
Mallia Therapeutics 與 Northway Biotech 宣布合作生產可溶性 CD83 蛋白 用於脫髮治療 |
| Mallia Therapeutics（「Mallia」）是一家致力於開發新型脫髮治療方案的生物製藥公司，Northway Biotech（「NBT」）則是一家專業從事生物製劑的合同開發與製造組織（CDMO）。雙方宣布建立合作夥伴關係，共同開發 Mallia 的可溶性 CD83 蛋白（sCD83）生產工藝，並負責其製造，該治療方案旨在促進毛囊形成與生長。 more info >> |
|
| Tuesday, February 4, 2025 |
|
|
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment |
| Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth. more info >> |
|
| Tuesday, August 1, 2023 |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
How Do AI Workflow Automations Work?
Aug 16, 2025 00:00 HKT/SGT
|
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 15, 2025 23:18 HKT/SGT
|
|
|
Yuexiu REIT Maintains Overall Operational Stability, Achieves Revenue of Over RMB966 Million
Aug 15, 2025 23:17 HKT/SGT
|
|
|
The 35th Food Expo opens today
Aug 15, 2025 23:16 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 15, 2025 23:06 HKT/SGT
|
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT/SGT
|
|
|
艾曲莫德入選《2025 ACG臨床指南：成人潰瘍性結腸炎》，獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療
Aug 15, 2025 20:07 HKT/SGT
|
|
|
艾曲莫德入选《2025 ACG临床指南：成人溃疡性结肠炎》，获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗
Aug 15, 2025 19:56 HKT/SGT
|
|
|
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively
Aug 15, 2025 19:11 HKT/SGT
|
|
|
業聚醫療2025年中期業績收入及純利雙雙增長 分別達8,360萬美元及1,980萬美元
Aug 15, 2025 18:53 HKT/SGT
|
|
|
业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元
Aug 15, 2025 18:10 HKT/SGT
|
|
|
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
Aug 15, 2025 18:00 HKT/SGT
|
|
|
廣發証券榮膺國家數據管理能力成熟度（DCMM）最高等級認証
Aug 15, 2025 17:28 HKT/SGT
|
|
|
米国株式アクティブ残高10年連続世界No.1ティー・ロウ・プライス[1] 日本法人が既存追加型株式投資信託に「毎月決算・予想分配金提示型」ファンドを新規設定
Aug 15, 2025 17:15: JST
|
|
|
广发证券荣膺国家数据管理能力成熟度（DCMM）最高等级认证
Aug 15, 2025 17:12 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
